港股早評:三大指數高開 創新藥概念股繼續上升 新琪安、容大科技首日上市開升逾60%
隔夜美股納指、標普500指數創階段新高,中概指數大升超2%。昨日強勢的的港股三大指數高開,恒指升0.21%,國指升0.22%,恒生科技指數升0.41%。盤面上,大型科技股多數繼續上升,快手升2.56%,小米升1%,阿里巴巴、百度、騰訊均有升幅,美團、網易飄綠;創新藥概念股繼續上升,君實生物、歌禮制藥升超3%;核電股上升明顯,中廣核礦業升超5%,煤炭股集體上升,兗煤澳大利亞升4.7%,兗礦能源升近3%,餐飲股、軟件類股、特斯拉概念股普升。另一方面,中資券商股、黃金股、鋼鐵股部分走低,權重中金公司跌近2%。另外,“代糖巨頭”新琪安首日高開60.05%;“AIDC裝置供應商”容大科技首日高開66%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.